Favorable regulations and high patient volumes to augment growth rates
SINGAPORE, March 26, 2018 /PRNewswire/ — Frost & Sullivan’s latest analysis of the APAC biosimilars market finds patent expiries, better-defined regulatory pathways, and escalating healthcare costs will…